Robeco Institutional Asset Management B.V. Decreases Holdings in Royalty Pharma PLC $RPRX

Key Points

• Robeco Institutional Asset Management trimmed its stake in Royalty Pharma by 24.0% in Q4, selling 299,147 shares and finishing the quarter with 949,472 shares worth about $36.69 million (0.16% of the company).
• Company insiders have been active sellers — CFO Terrance P. Coyne sold 114,954 shares (~$4.92M) and insiders have sold 477,496 shares (~$20.41M) in the last 90 days, leaving insiders with 18.9% ownership.
• Analysts remain largely bullish with an average rating of "Buy" and a consensus target of $49.00; RPRX trades near $48.43, with a market cap of about $27.94 billion and a P/E of 35.87.

Robeco Institutional Asset Management B.V. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 24.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 949,472 shares of the biopharmaceutical company's stock after selling 299,147 shares during the period. Robeco Institutional Asset Management B.V. owned 0.16% of Royalty Pharma worth $36,688,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in RPRX. Smartleaf Asset Management LLC lifted its holdings in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. Financial Consulate Inc. purchased a new position in Royalty Pharma during the third quarter valued at $35,000. Larson Financial Group LLC lifted its holdings in Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 306 shares in the last quarter. Richardson Financial Services Inc. purchased a new position in Royalty Pharma during the third quarter valued at $54,000. Finally, Farther Finance Advisors LLC lifted its holdings in Royalty Pharma by 44.3% during the third quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 632 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $48.43 on Tuesday. The company's 50-day moving average price is $46.04 and its 200-day moving average price is $41.22. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The company has a market cap of $27.94 billion, a P/E ratio of 35.87, a P/E/G ratio of 3.06 and a beta of 0.39. Royalty Pharma PLC has a twelve month low of $31.58 and a twelve month high of $49.06.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. The firm had revenue of $621.99 million for the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. On average, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 114,954 shares of Royalty Pharma stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the transaction, the chief financial officer directly owned 23,972 shares of the company's stock, valued at $1,026,960.48. The trade was a 82.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00. Following the transaction, the executive vice president directly owned 40,000 shares in the company, valued at $1,580,800. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 477,496 shares of company stock worth $20,408,425 over the last ninety days. 18.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on RPRX shares. UBS Group raised shares of Royalty Pharma from a "neutral" rating to a "buy" rating and set a $49.00 price objective on the stock in a report on Friday, January 30th. Weiss Ratings raised shares of Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, February 12th. The Goldman Sachs Group reissued a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Wall Street Zen downgraded shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Finally, TD Cowen reissued a "buy" rating on shares of Royalty Pharma in a research note on Friday, February 27th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $49.00.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.